Mira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.
